Sep 2026
Abstract B045: Plasma cfDNA 5-hydroxymethylcytosine signatures associate with treatment response and molecular subtype in BRCA -mutant pancreatic cancer
Biomarkers that predict and monitor response to platinum-based chemotherapy and PARP-inhibitor (PARPi) therapy remain an unmet need in BRCA-positive pancreatic ductal adenocarcinoma (PDAC). Furthermore, blood-based assays to classify tumor expression subtypes are limited. Cell-free DNA (cfDNA) 5-hydroxymethylcyto...
Ceyda Çoruh, M. Raitses-Gurevich, Y. Ning et al.
· Cancer Research · 0 citations